TH9507

TH9507

$130.00

Research Use Only | Not for Human Consumption

A synthetic 44-amino-acid analog of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoic acid modification at Tyr1

Published February 4, 2026 · Reviewed by the Peptide Foundry Research Team

A synthetic GHRH analog stabilized by an N-terminal trans-3-hexenoic acid group that resists enzymatic degradation. Published preclinical and clinical research has examined its interactions with the pituitary GHRH receptor (GHRHR) and downstream somatotroph signaling pathways.

CAS#FormulaMolar Mass
218949-48-5C₂₂₁H₃₆₆N₇₂O₆₇S5135.9 g/mol

All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.

Join Foundry Club$50/monthGet this for $95 — Save $35

A 44-amino-acid GHRH analog with a trans-3-hexenoic acid modification; CAS 218949-48-5

Category:

What is TH9507?

TH9507 was developed in the early 2000s by Theratechnologies, a Canadian pharmaceutical company based in Montreal. The research team worked on analogs of growth hormone-releasing hormone (GHRH), building on earlier structural work with the native 44-amino-acid peptide.

The molecule is distinguished by a trans-3-hexenoic acid group attached to the tyrosine at position 1. In preclinical characterization, this modification resists enzymatic breakdown while preserving receptor-binding activity of the parent GHRH sequence.

The compound has since appeared in multiple clinical trials and published preclinical investigations of the GHRH receptor (GHRHR) and associated somatotroph signaling pathways. This product is intended for research use only.

What is TH9507 studied for?

The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.

Visceral Adipose Tissue Research u2014 Human

In clinical trials in HIV-associated lipodystrophy populations, TH9507 has been examined for its associations with visceral adipose tissue measurements on imaging.

View Studies (1)

Lipid Panel Research u2014 Human

Human studies have examined TH9507's associations with triglyceride, cholesterol, and related lipid-panel measurements.

View Studies (1)

Hepatic Steatosis Research u2014 Human

Clinical trials have examined TH9507's associations with liver-fat fraction measured by MRS and related hepatic-steatosis endpoints in HIV populations.

View Studies (1)

IGF-1 Axis Research u2014 Human

Published investigations have examined TH9507's interactions with the GHRH-receptor-mediated IGF-1 axis and associated serum IGF-1 measurements.

View Studies (1)

How should TH9507 be stored?

All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.

Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.

After reconstitution, the peptides will remain stable for up to 30 days.

Certificate of Analysis

All TH9507 batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.

HPLC Purity

—

COA documents are updated with each new batch. Contact support for batch-specific documentation.

Related Research Compounds

Frequently purchased with TH9507

Ipamorelin

Ipamorelin

10mg

$60

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin

5mg/5mg

$85

Sermorelin

Sermorelin

10mg

$110

Add all 3 items to your cart

$255

Clinical References

  1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007. PubMed: 18057338
  2. Stanley TL, et al. Effect of th9507 on visceral fat and liver fat in HIV-infected patients. JAMA. 2014. PubMed: 25038357
  3. Falutz J, et al. TH9507 reduces trunk fat in HIV-infected patients. Journal of Clinical Endocrinology & Metabolism. 2007. PubMed: 20101189
  4. Makimura H, et al. The effects of th9507 on hepatic triglyceride content. Journal of Clinical Endocrinology & Metabolism. 2015.

TH9507 is available for laboratory research purposes only.

© 2026 Peptide Foundry LLC | Product Catalog | Research Use Only

Related products

Welcome!

I understand these products are for research use only and not for use in people or pets. I am purchasing these items for laboratory or research purposes only. They are not for human or animal use, not medicine, and not for diagnosing, treating, or curing any condition. I will follow all applicable laws and safe handling rules. I accept that this website, and our affiliates, are not responsible for how I use or store these items once delivered, to the fullest extent allowed by law. In accordance with industry guidelines, access to this website is restricted to individuals 21 years of age or older. This site provides information and products strictly for laboratory and research use. Are you over 21 years of age?

I am I am not

Remember Me
Disclaimer: -Peptides: This product is intended for laboratory research use only and is not approved for human consumption, medical, or veterinary use. Peptides are sold solely for research and development purposes by qualified professionals. Buyers are responsible for handling all materials in accordance with local regulations and safety guidelines. Waave Compliance blocks all international shipping. FDA disclaimer: The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure, or prevent any disease.